Dr. Renata Ferrarotto
Claim this profileM D Anderson Cancer Center
Studies Parotid Gland Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
21 drugs studied
Area of expertise
1Parotid Gland Cancer
Stage IV
Stage III
NOTCH1 positive
2Squamous Cell Carcinoma
Stage IV
HPV16 positive
Stage II
Affiliated Hospitals
Clinical Trials Renata Ferrarotto is currently running
Sacituzumab Govitecan
for Salivary Gland Cancer
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Recruiting1 award Phase 2
REM-422
for Advanced Cancer
This trial is testing REM-422, an oral medicine, in people with advanced Adenoid Cystic Carcinoma (ACC) that has returned or spread. REM-422 aims to reduce a protein needed for cancer growth by breaking down its mRNA. The study will determine the best dose and evaluate its safety and effectiveness.
Recruiting1 award Phase 116 criteria
More about Renata Ferrarotto
Clinical Trial Related3 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Renata Ferrarotto has experience with
- Docetaxel
- Pembrolizumab
- Cemiplimab
- Cisplatin
- ISA101b
- Sacituzumab Govitecan
Breakdown of trials Renata Ferrarotto has run
Parotid Gland Cancer
Squamous Cell Carcinoma
Adenoid Cystic Carcinoma
Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Renata Ferrarotto specialize in?
Is Renata Ferrarotto currently recruiting for clinical trials?
Are there any treatments that Renata Ferrarotto has studied deeply?
What is the best way to schedule an appointment with Renata Ferrarotto?
What is the office address of Renata Ferrarotto?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.